”We are very happy to get a highly recognized IPR expert both in Finland and internationally to further strengthen our team of talented professionals. In his new position, Johansson will drive the development of our company’s customerships and our entire operational environment. He will bring in new experience and assets needed in application, dispute and IPR strategy matters”, said Markku Simmelvuo, Managing Director, Papula-Nevinpat.
Johansson commented on his new position: ”I am extremely excited to become part of the Papula-Nevinpat team dedicated to strengthening Papula-Nevinpat’s position as one of the leading patent and trademark agencies in Finland and Eurasia. This new role gives me a great opportunity to utilize my IPR experience and to expand my knowledge of the Finnish and international business environment. Papula-Nevinpat’s varied and international clientele offers me deep insight to various technological fields. I am confident that I will be able to introduce new operating models to Papula-Nevinpat’s customers as well as within the company.”
Papula-Nevinpat
Papula-Nevinpat is a globally recognized patent, trademark and design agency. In addition to our Finland-based global operations, Papula-Nevinpat has a strong foothold in the Eurasian territory with local offices in Russia, Belarus, Kazakhstan, Ukraine, and Uzbekistan. Our attorneys will help you secure your exclusive rights anywhere in the world.
www.papula-nevinpat.com
Media enquiries:
Papula-Nevinpat
Markku Simmelvuo, Managing Director
Tel. +358 40 545 4484
Papula-Nevinpat
Marika Kojo, Communications Manager
Tel. +358 400 816 384
Papula-Nevinpat’s trademark practice has once again been recognized in the top tier of the 2025 edition of the World Trademark Review 1000.
Papula-Nevinpat is pleased to continue as the ESA BIC Finland program's intellectual property rights (IPR) partner.
Wishing you a warm and joyful holiday season!
Riikka Palmos, a European Trademark Attorney, has authored an article discussing key developments in Ukraine and Russia. You can read the article in the latest PTMG (Pharmaceutical Trade Marks Group) newsletter.
